Disis ML, et al. - Researchers examined the clinical activity of avelumab, an anti–programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer, in an expansion cohort of a phase 1b, open-label study (JAVELIN Solid Tumor). They administered avelumab, 10 mg/kg, every 2 weeks, to 125 patients with heavily pretreated ovarian cancer (median, 3 prior lines). Outcomes showed the objective response rate of 9.6%, complete response in 1 patient (0.8%), the 1-year progression-free survival rate of 10.2%, median overall survival of 11.2 months. In 7.2% of patients, grade 3 or 4 treatment-related adverse events occurred and in 16.8% of patients, immune-related adverse events occurred. Findings thus support antitumor activity and an acceptable safety profile of avelumab in these heavily pretreated ovarian cancer patients.